Matisse Pharmaceuticals B.V.
Matisse Pharmaceuticals B.V. is a biopharmaceutical clinical stage company based in Geleen, The Netherlands. Founded in 2014, the company is dedicated to developing innovative therapies targeting life-threatening inflammation, particularly in sepsis and septic shock. Their mission is to save millions of lives by effectively neutralizing extracellular cytotoxic histones, with a vision to become the first company worldwide to effectively combat sepsis.
Matisse Pharmaceuticals B.V.
Burgemeester Lemmensstraat 352, P.O. Box 1124, 6160 BC Geleen, The Netherlands
What We Do
M6229 is a Low Anticoagulant Molecule (LAM) fraction of heparin, developed to neutralize toxic extracellular histones in sepsis patients. It is currently in phase I/IIa development, demonstrating efficacy in multiple animal sepsis models and is now in the clinical stage.
An advanced version of M6229, developed in partnership with the University of Maastricht, aiming for an improved mechanism of action targeting multiple disease areas.
Infectious Diseases
Drugs
Key People
Chief Executive Officer
Chief Development Officer
Chief Operational Officer
Chief Scientific Officer
Scientific Advisory Board Member
News & Updates
Matisse Pharmaceuticals received approval from the German Regulatory Authorities to start a phase 1 study evaluating the safety, tolerability, and pharmacokinetics of a prolonged intravenous infusion with its lead compound M6229.
Prof. Carolyn Calfee, an expert in critical care and respiratory infections, joins the Scientific Advisory Board of Matisse Pharmaceuticals.